Association of serum anti-gbs2106 protein immunoglobulin G (IgG) in newborns and risk reduction of invasive group B streptococcus disease during early infancy., PMID:40088514
Characterization of the Cellular Immune Response to Group B Streptococcal Vaginal Colonization., PMID:39975125
Impact of HIV Status on Group B Streptococcus Colonization and Antibody Responses in Serum and Vaginal Mucosa., PMID:39951074
Group B Streptococcal Membrane Vesicles Induce Proinflammatory Cytokine Production and Are Sensed in an NLRP3 Inflammasome-Dependent Mechanism in a Human Macrophage-like Cell Line., PMID:39761308
Diversity in Naturally Acquired Immunity to Group B Streptococcus: A Comparative Study of Women From Bangladesh, Malawi, and the United Kingdom., PMID:39692506
Effect of the MONTANIDE™ IMS 1312 adjuvant on the innate and adaptive immune responses of Nile tilapia (Oreochromis niloticus) against Streptococcusagalactiae through immersion vaccination., PMID:39510429
Serological Responses to Target Streptococcus pyogenes Vaccine Antigens in Patients With Proven Invasive β-Hemolytic Streptococcal Infections., PMID:39383256
Neonatal intestinal colonization of Streptococcus agalactiae and the multiple modes of protection limiting translocation., PMID:39042143
Introducing Triplex Forming Oligonucleotide into Loop-Mediated Isothermal Amplification for Developing a Lateral Flow Biosensor for Streptococci Detection., PMID:38785731
Antibody kinetics between birth and three months of life in healthy infants with natural exposure to Group B streptococcus: A UK cohort study., PMID:38627147
Development and validation of a 6-plex Luminex-based assay for measuring human serum antibodies to group B streptococcus capsular polysaccharides., PMID:38608171
Interlaboratory comparison of a multiplex immunoassay that measures human serum IgG antibodies against six-group B streptococcus polysaccharides., PMID:38608170
Engagement of α3β1 and α2β1 integrins by hypervirulent Streptococcus agalactiae in invasion of polarized enterocytes., PMID:38511003
Maternal GBS vaccination for preventing group B streptococcus disease in newborns: A mini review of current evidence., PMID:38445529
The Group A Streptococcal Vaccine Candidate VAX-A1 Protects against Group B Streptococcus Infection via Cross-Reactive IgG Targeting Virulence Factor C5a Peptidase., PMID:38140215
The immunogenicity and safety of Group B Streptococcal maternal vaccines: A systematic review., PMID:38072754
Placental Streptococcus agalactiae DNA is associated with neonatal unit admission and foetal pro-inflammatory cytokines in term infants., PMID:38030897
Preclinical development of a novel Group B Streptococcus (GBS) vaccine candidate for maternal immunization based upon the alpha-like protein family of GBS surface proteins (Alp)., PMID:37010372
Association of infant Rib and Alp1 surface protein N-terminal domain immunoglobulin G and invasive Group B Streptococcal disease in young infants., PMID:36754766
Attenuated Streptococcus agalactiae WC1535 ∆Sia perturbs the gut microbiota of Oreochromis niloticus, massively colonizes the intestine, and induces intestinal mucosal immunity after intraperitoneal inoculation., PMID:36439833
Sublingual immunisation with GBS serotype III capsular polysaccharide-tetanus toxoid conjugate vaccine induces systemic and mucosal antibody responses which are opsonophagocytic and inhibit GBS colonisation of vaginal epithelial cells., PMID:36096970
Development and evaluation of a multi-epitope subunit vaccine against group B Streptococcus infection., PMID:36069613
The Streptococcus agalactiae R3 surface protein is encoded by sar5., PMID:35905090
Group B Streptococcus (GBS) colonization is dynamic over time, whilst GBS capsular polysaccharides-specific antibody remains stable., PMID:35802786
Construction of Streptococcus agalactiae sialic acid mutant and evaluation of its potential as a live attenuated vaccine in Nile tilapia (Oreochromis niloticus)., PMID:35801502
Methodology for a correlate of protection for group B Streptococcus: Report from the Bill & Melinda Gates Foundation workshop held on 10 and 11 February 2021., PMID:35779963
A Recombinant Alpha-Like Protein Subunit Vaccine (GBS-NN) Provides Protection in Murine Models of Group B Streptococcus Infection., PMID:35429401
Estimation of invasive Group B Streptococcus disease risk in young infants from case-control serological studies., PMID:35350991
A group B Streptococcus alpha-like protein subunit vaccine induces functionally active antibodies in humans targeting homotypic and heterotypic strains., PMID:35243418
Advances towards licensure of a maternal vaccine for the prevention of invasive group B streptococcus disease in infants: a discussion of different approaches., PMID:35240933
Infant serotype specific anti-capsular immunoglobulin G antibody and risk of invasive group B Streptococcal disease., PMID:34688499
Development and Immunogenicity of a Prototype Multivalent Group B Streptococcus Bioconjugate Vaccine., PMID:34633812
Maternal immunization with Group B Streptococcus six-valent polysaccharide conjugate vaccine supported by lack of toxicity in rat and rabbit fertility and developmental toxicity studies., PMID:34516044
The Recombinant Expression Proteins FnBP and ClfA From Staphylococcus aureus in Addition to GapC and Sip From Streptococcus agalactiae Can Protect BALB/c Mice From Bacterial Infection., PMID:34250059
Safety and immunogenicity of a prototype recombinant alpha-like protein subunit vaccine (GBS-NN) against Group B Streptococcus in a randomised placebo-controlled double-blind phase 1 trial in healthy adult women., PMID:34215454
Development and Validation of Enzyme-Linked Immunosorbent Assay for Group B Streptococcal Polysaccharide Vaccine., PMID:34064299
Association of Group B Streptococcus (GBS) Serum Serotype-Specific Anticapsular Immunoglobulin G Concentration and Risk Reduction for Invasive GBS Disease in South African Infants: An Observational Birth-Cohort, Matched Case-Control Study., PMID:33341870
Clinical utilization of species-specific immunoassays for identification of Staphylococcus aureus and Streptococcus agalactiae in orthopedic infections., PMID:33274775
Prevalence of Capsular Serotype, Pilus Island Distribution, and Antibiotic Resistance in Pediatric and Adult Invasive Group B Streptococcus Isolates: Data From a Nationwide Prospective Surveillance Study in Germany., PMID:33201062
The Impact of Circulating Antibody on Group B Streptococcus Intestinal Colonization and Invasive Disease., PMID:33077619
Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial., PMID:32891191
Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in pregnant women and their infants: Results from a randomized placebo-controlled phase II trial., PMID:32883555
Immunization with a recombinant BibA surface protein confers immunity and protects mice against group B Streptococcus (GBS) vaginal colonization., PMID:32571719
Lipid analogs reveal features critical for hemolysis and diminish granadaene mediated Group B Streptococcus infection., PMID:32198389
Safety and immunogenicity of fully liquid and lyophilized formulations of an investigational trivalent group B streptococcus vaccine in healthy non-pregnant women: Results from a randomized comparative phase II trial., PMID:32169390
Age-stratified analysis of serotype-specific baseline immunity against group B streptococcus., PMID:31687869
Rapid detection of Group B Streptococcus (GBS) from artificial urine samples based on IFAST and ATP bioluminescence assay: from development to practical challenges during protocol testing in Kenya., PMID:31621696
Modulation of Death and Inflammatory Signaling in Decidual Stromal Cells following Exposure to Group B Streptococcus., PMID:31548323
Genetically distinct Group B Streptococcus strains induce varying macrophage cytokine responses., PMID:31536604
Safety and Immunogenicity of a Second Dose of an Investigational Maternal Trivalent Group B Streptococcus Vaccine in Nonpregnant Women 4-6 Years After a First Dose: Results From a Phase 2 Trial., PMID:31394574
For research use only. Not for human or drug use.
